Illinois 2023-2024 Regular Session

Illinois House Bill HB2814

Introduced
2/16/23  
Introduced
2/16/23  
Refer
2/28/23  
Refer
2/16/23  
Refer
3/10/23  
Refer
2/28/23  

Caption

INS-CLINICIAN ADMINISTER DRUG

Impact

The legislation is expected to enhance patient rights by mitigating restrictive practices imposed by health benefit plans. By prohibiting policies that limit the choices of pharmacies or healthcare providers, HB2814 facilitates a more patient-centered approach to accessing necessary medications. Additionally, it aligns the state regulations with federal guidelines under the Drug Supply Chain Security Act, ensuring that clinician-administered drugs meet prescribed supply chain security standards. This alignment could be beneficial in maintaining the integrity and safety of drug distribution across Illinois.

Summary

House Bill 2814, introduced by Rep. Camille Y. Lilly, amends the Illinois Insurance Code to impose specific prohibitions on health benefit plans that provide coverage for prescription drugs. Effective from January 1, 2023, the bill stipulates that enrollees cannot be required to engage in certain prohibited acts regarding the sourcing and administration of clinician-administered drugs. This includes steering enrollees to specific pharmacies selected by the health benefit plan, conditioning coverage based on pharmacy selection, and imposing higher out-of-pocket costs for using non-preferred providers or pharmacies. Such provisions aim to ensure equitable access to medication and reduce barriers for patients needing clinician-administered drugs.

Contention

While proponents argue that HB2814 will protect consumers and improve access to essential medications, critics point to potential complications in managing pharmacy benefits. Concerns have been raised regarding the economic implications for pharmacy benefit managers and the healthcare system as a whole. Opposition voices emphasize that increased regulations on pharmacy benefits might lead to higher costs or non-compliance issues for health plans, potentially resulting in unintended consequences for both providers and patients. The balance between regulatory measures and market operations remains a critical point of discussion as the bill progresses through the legislative process.

Companion Bills

No companion bills found.

Previously Filed As

IL SB0311

INS CODE-RIDING THERAPY

IL SB2744

INS-VACCINE ADMINISTRATION FEE

IL SB1708

INS-EMPLOYMENT/HEALTH BENEFITS

IL SB1527

INS-HEALTH BENEFITS

IL SB1255

INS-CLINICIAN ADMINISTER DRUG

IL HB2445

INS-SENIOR FITNESS COVERAGE

IL HB3202

INS-HEALTH/SALIVA CANCER TEST

IL HB3183

INS-HEALTH/CORONARY SCAN

Similar Bills

AK HB226

Pharmacies/pharmacists/benefits Managers

AK SB121

Pharmacies/pharmacists/benefits Managers

IL SB1255

INS-CLINICIAN ADMINISTER DRUG

IL SB3225

INS-CLINICIAN ADMINISTER DRUG

FL H0203

Access to Pharmacies and Prescription Drugs Under Insurance and Pharmacy Benefit Managers Policies

IL SB1746

INS-CLINICIAN ADMINISTER DRUG

IN HB1158

Health and human services matters.

NH SB256

Relative to the affordability and safety of clinician administered drugs.